Posted by Michael Wonder on 12 Aug 2020
Health Canada approves Opdivo (nivolumab) plus Yervoy (ipilimumab) combined with limited chemotherapy for the treatment of metastatic non-small cell lung cancer
11 August 2020 - CheckMate-9LA trial results demonstrated superior overall survival versus chemotherapy, regardless of PD-L1 expression or tumour histology.
Today, Bristol Myers Squibb Canada announces Health Canada's approval of Opdivo (nivolumab) in combination with Yervoy (ipilimumab) with two cycles of platinum-double chemotherapy for the treatment of patients with metastatic non-small cell lung cancer (NSCLC), with no epidermal growth factor receptor or anaplastic lymphoma kinase tumour aberrations and no prior systemic therapy for metastatic NSCLC.
Unlike traditional cancer therapies that target the tumour directly, immuno-oncology activates the body's own immune system to help recognise and attack cancer cells. This approval marks the availability of the first dual immuno-oncology plus limited course chemotherapy NSCLC treatment in Canada.
